167 related articles for article (PubMed ID: 24075517)
1. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells.
Takiuchi D; Eguchi H; Nagano H; Iwagami Y; Tomimaru Y; Wada H; Kawamoto K; Kobayashi S; Marubashi S; Tanemura M; Mori M; Doki Y
Pancreatology; 2013; 13(5):517-23. PubMed ID: 24075517
[TBL] [Abstract][Full Text] [Related]
2. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
Iwagami Y; Eguchi H; Nagano H; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Tomokuni A; Tomimaru Y; Mori M; Doki Y
Br J Cancer; 2013 Jul; 109(2):502-11. PubMed ID: 23799850
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of isosteviol sodium through increasing CYLD by the downregulation of miRNA-181b.
Zhang H; Zhong K; Lu M; Mei Y; Tan E; Sun X; Tan W
Brain Res Bull; 2018 Jun; 140():392-401. PubMed ID: 29807144
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway.
Xu DD; Zhou PJ; Wang Y; Zhang L; Fu WY; Ruan BB; Xu HP; Hu CZ; Tian L; Qin JH; Wang S; Wang X; Li YC; Liu QY; Ren Z; Zhang R; Wang YF
Mol Cancer; 2016 May; 15(1):40. PubMed ID: 27189061
[TBL] [Abstract][Full Text] [Related]
5. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
[TBL] [Abstract][Full Text] [Related]
6. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
[TBL] [Abstract][Full Text] [Related]
7. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
8. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
9. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
[TBL] [Abstract][Full Text] [Related]
10. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer.
Iliopoulos D; Jaeger SA; Hirsch HA; Bulyk ML; Struhl K
Mol Cell; 2010 Aug; 39(4):493-506. PubMed ID: 20797623
[TBL] [Abstract][Full Text] [Related]
11. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
[TBL] [Abstract][Full Text] [Related]
12. Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis.
Li C; Zhao Z; Zhou Z; Liu R
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1199-1207. PubMed ID: 27785603
[TBL] [Abstract][Full Text] [Related]
13. microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1.
Yu Q; Xiu Z; Jian Y; Zhou J; Chen X; Chen X; Chen C; Chen H; Yang S; Yin L; Zeng W
Aging (Albany NY); 2022 Jul; 14(14):5908-5924. PubMed ID: 35896012
[TBL] [Abstract][Full Text] [Related]
14. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
15. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
[TBL] [Abstract][Full Text] [Related]
18. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
Mamaghani S; Patel S; Hedley DW
BMC Cancer; 2009 Apr; 9():132. PubMed ID: 19405981
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling.
Xia JT; Chen LZ; Jian WH; Wang KB; Yang YZ; He WL; He YL; Chen D; Li W
J Transl Med; 2014 Feb; 12():33. PubMed ID: 24495516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]